ArticleFrontiers in oncology2026
Case Report: Concomitant BRAF V600E and PIK3CA H1047R mutations in a micro-papillary thyroid carcinoma with extensive nodal metastasis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most papillary thyroid carcinoma (PTC) cases follow an indolent clinical course, a small subset presents with early extensive lymph node metastasis. Although this aggressive phenotype is frequently linked to the BRAF V600E mutation, concurrent activating mutations in the PI3K/AKT pathway, such as PIK3CA H1047R, are exceedingly rare and their clinical significance remains poorly understood. We report the case of a 42-year-old male with a 7.8-mm solitary papillary thyroid microcarcinoma (PTMC) harboring concurrent BRAF V600E and PIK3CA H1047R mutations. Despite the small size of the primary lesion, extensive cervical lymph node metastases were identified in at least five nodal levels. Although the primary tumor was classified as a low-risk by conventional size-based criteria, the presence of these two oncogenic drivers suggests disproportionately aggressive lymph node dissemination relative to tumor size, underscoring the value of expanded molecular profiling for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.